Amgen Inc.
AMGN · Nasdaq
AMGN · Nasdaq
The supplied consensus is Hold across 24 analysts, with a mean price target of $400; low and high targets are not available, so the target spread and named bullish and bearish extremes cannot be established. HSBC analyst Morten Herholdt was the clearest negative revision during the week, downgrading Amgen from Buy to Hold and cutting his target from $445 to $425. Other supplied snippets describe the broader target as having moved slightly lower to about $350, but do not identify a specific analyst action. The substantive disagreement is valuation versus pipeline risk: bullish commentary sees the selloff as excessive and points to fair-value support or oncology progress, while more cautious analysts see trial-related uncertainty and limited target upside. No firm-specific revision trend beyond HSBC is explicitly documented.
